Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.72 |
| ▸ | CA1 | P00915 | 2/20 | 0.72 |
| ▸ | CA2 | P00918 | 2/20 | 0.72 |
| ▸ | CA9 | Q16790 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.71 |
| ▸ | IDH1 | O75874 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004795 | 0.86 | BAZ1A (0.64) | CA12CA1CA2CA9MAPT | |
| SCHEMBL4002880 | 0.84 | MAPT (0.68) | CA12CA1CA2CA9MAPT | |
| SCHEMBL28729179 | 0.84 | EPHX2 (1.00) | CA12CA1CA2CA9MAPT | |
| SCHEMBL11003408 | 0.84 | EPHX2 (1.00) | CA12CA1CA2CA9MAPT | |
| SCHEMBL668108 | 0.84 | CA1 (1.00) | CA12CA1CA2CA9MAPT | |
| SCHEMBL20725356 | 0.83 | IDH1 (1.00) | IDH1 | |
| SCHEMBL863126 | 0.82 | PTGS2 (0.68) | CA1CA2AKR1C3 | |
| SCHEMBL5594038 | 0.82 | TRPV4 (0.54) | CA12CA1CA2CA9MAPT | |
| SCHEMBL4005055 | 0.82 | IDO1 (0.65) | CA12CA1CA2CA9MAPT | |
| SCHEMBL3346579 | 0.81 | MAPT (0.68) | CA12CA1CA2CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. | 2009-10-29 | — | — | US | claimed |
| WO-2009129501-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | WO | claimed |
| CN-101516838-A | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS INC (US) | 2009-08-26 | — | — | CN | claimed |
| EP-2069294-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080207622-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | claimed |
| WO-2008039999-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-20100063583-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES | ARETE THERAPEUTICS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100063583-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES | ARETE THERAPEUTICS, INC. | 2010-03-11 | — | — | US | disclosed |
| WO-2010025043-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES | ARETE THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009129501-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129501-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| EP-2069294-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080207622-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207622-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207622-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2008039999-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039999-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | EPHX1, PTGIS, PDE3A | CA12 4380/4885CA1 2937/4885CA2 2929/4885 |
| US-20100063583-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES | ALOX15B, ALOX15, ALOX12 | CA12 1900/4885CA1 856/4885CA2 1480/4885 |
| US-20080207622-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | CA12 2404/4885CA1 1212/4885CA2 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.